His primary areas of study are Internal medicine, Endocrinology, Nonalcoholic fatty liver disease, Insulin resistance and Fatty liver. Internal medicine is closely attributed to Gastroenterology in his work. His research in Gastroenterology tackles topics such as Genotype which are related to areas like Adiponutrin.
His Endocrinology research incorporates elements of Hemochromatosis, Hereditary hemochromatosis, Inflammation, Case-control study and TM6SF2. His research integrates issues of Fibrosis, Heterozygote advantage, Chronic liver disease and Type 2 diabetes in his study of Nonalcoholic fatty liver disease. The Fatty liver study combines topics in areas such as Diabetes mellitus, Liver disease and Lipid droplet.
Luca Valenti spends much of his time researching Internal medicine, Gastroenterology, Fatty liver, Endocrinology and Nonalcoholic fatty liver disease. His work on Steatosis, Insulin resistance, Cirrhosis and Liver disease as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His Gastroenterology study incorporates themes from Liver biopsy, Fibrosis, Pathology, Hepatocellular carcinoma and Genotype.
His study in Fatty liver is interdisciplinary in nature, drawing from both Case-control study and Cohort. His study looks at the intersection of Endocrinology and topics like Hepcidin with Ferritin. Luca Valenti has researched Nonalcoholic fatty liver disease in several fields, including Liver damage, Lipogenesis, Metabolic syndrome and Type 2 diabetes.
His primary areas of investigation include Internal medicine, Fatty liver, Gastroenterology, Disease and Steatosis. Internal medicine connects with themes related to Endocrinology in his study. His Fatty liver study combines topics in areas such as Cohort and Bioinformatics.
His Gastroenterology study integrates concerns from other disciplines, such as Fibrosis, Autoimmune hepatitis, Risk stratification and Anemia. He has included themes like Genome-wide association study, Pathophysiology, Type 2 diabetes and Genetic association in his Disease study. The concepts of his Steatosis study are interwoven with issues in Lipid metabolism, Liver biopsy and Hepatic stellate cell.
His main research concerns Internal medicine, Fatty liver, Steatosis, Disease and Steatohepatitis. His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Endocrinology and Antibody. His Fatty liver research integrates issues from Diabetes mellitus, Chronic liver disease, Cirrhosis and Bioinformatics.
His study focuses on the intersection of Steatosis and fields such as Hepatic stellate cell with connections in the field of Macrophage, Receptor, Tyrosine kinase and Hepatic fibrosis. His work in Disease addresses issues such as Genome-wide association study, which are connected to fields such as Meta-analysis and Locus. The various areas that Luca Valenti examines in his Steatohepatitis study include Nonalcoholic fatty liver disease and Hepatocyte.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
Anna Ludovica Fracanzani;Luca Valenti;Elisabetta Bugianesi;Marco Andreoletti.
Genomewide Association Study of Severe Covid-19 with Respiratory Failure.
David Ellinghaus;Frauke Degenhardt;Luis Bujanda;Maria Buti.
The New England Journal of Medicine (2020)
Nuclear Trapping of the Forkhead Transcription Factor FoxO1 via Sirt-dependent Deacetylation Promotes Expression of Glucogenetic Genes
David Frescas;Luca Valenti;Domenico Accili.
Journal of Biological Chemistry (2005)
Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease
Luca Valenti;Ahmad Al‐Serri;Ann K. Daly;Enrico Galmozzi.
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam;Philip N. Newsome;Shiv K. Sarin;Quentin M. Anstee.
Journal of Hepatology (2020)
Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease
Luca Valenti;Anna Ludovica Fracanzani;Paola Dongiovanni;Gennaro Santorelli.
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Mohammed Eslam;Luca Valenti;Stefano Romeo.
Journal of Hepatology (2018)
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent
Rosellina Margherita Mancina;Paola Dongiovanni;Salvatore Petta;Piero Pingitore.
Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target
Paola Dongiovanni;Anna Ludovica Fracanzani;Silvia Fargion;Luca Valenti.
Journal of Hepatology (2011)
Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease
Paola Dongiovanni;Salvatore Petta;Cristina Maglio;Anna Ludovica Fracanzani.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: